<DOC>
	<DOCNO>NCT01565408</DOCNO>
	<brief_summary>This trial conduct Europe . The aim dose-escalating trial ass safety tolerability multiple dose NNC0114-0006 subject rheumatoid arthritis ( RA ) .</brief_summary>
	<brief_title>Safety Tolerability NNC0114-0006 Increasing Dose Levels Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>A diagnosis RA , meeting 2010 ACREULAR ( American College RheumatologyEuropean League Against Rheumatism ) 1987 ACR classification criterion , make least 4 month prior trial drug administration Active RA , characterise DAS28CRP equal 4.5 least 5 tender 5 swollen joint Methotrexate ( MTX ) treatment least 16 week ( dose equal 7.5 mg/week equal 25 mg/week ) stable dose least 6 week prior dose Female subject pregnant nursing Subjects chronic inflammatory autoimmune disease RA Any active ongoing chronic infectious disease require systemic antiinfectious treatment within 4 week prior randomisation Body mass index ( BMI ) 18.0 35.0 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>